These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16433583)

  • 1. A review of erlotinib and its clinical use.
    Tang PA; Tsao MS; Moore MJ
    Expert Opin Pharmacother; 2006 Feb; 7(2):177-93. PubMed ID: 16433583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
    Mountzios G; Syrigos KN
    Drug Saf; 2011 Mar; 34(3):175-86. PubMed ID: 21332242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib in cancer treatment.
    Bareschino MA; Schettino C; Troiani T; Martinelli E; Morgillo F; Ciardiello F
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi35-41. PubMed ID: 17591829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
    Wacker B; Nagrani T; Weinberg J; Witt K; Clark G; Cagnoni PJ
    Clin Cancer Res; 2007 Jul; 13(13):3913-21. PubMed ID: 17606725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
    Welch SA; Moore MJ
    Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib in the treatment of non-small cell lung cancer.
    Brown ER; Shepherd FA
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):767-75. PubMed ID: 16221047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
    Gordon AN; Finkler N; Edwards RP; Garcia AA; Crozier M; Irwin DH; Barrett E
    Int J Gynecol Cancer; 2005; 15(5):785-92. PubMed ID: 16174225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib in glioblastoma: lost in translation?
    Karpel-Massler G; Westhoff MA; Kast RE; Wirtz CR; Halatsch ME
    Anticancer Agents Med Chem; 2011 Oct; 11(8):748-55. PubMed ID: 21707495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Iyer R; Bharthuar A
    Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
    Rhee J; Oishi K; Garey J; Kim E
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S101-6. PubMed ID: 16336749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
    Lee VW; Schwander B; Lee VH
    Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy: an evolving world of lung cancer.
    Lam KC; Mok TS
    Respirology; 2011 Jan; 16(1):13-21. PubMed ID: 20723139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.
    Gordon MS; Hussey M; Nagle RB; Lara PN; Mack PC; Dutcher J; Samlowski W; Clark JI; Quinn DI; Pan CX; Crawford D
    J Clin Oncol; 2009 Dec; 27(34):5788-93. PubMed ID: 19884559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erlotinib in the treatment of non-small cell lung cancer].
    Ostoros G; Döme B
    Magy Onkol; 2006; 50(3):237-41. PubMed ID: 17099784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erlotinib in non-small cell lung cancer].
    Takeda M; Okamoto I
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.